Clinical Trial Update: Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes [Phase 1, Phase 2]

View source ↗

Summary

This entry provides an update on a phase 1/2 gene therapy trial using CD19 CAR-T cells to treat relapsed or refractory B-cell non-Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• CD19 CAR T cells

Snippet

Sponsor: Jichi Medical University | Conditions: Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN